RFL
Rafael Holdings, Inc.
$2.24
+5.66%
$116.5M
No data for this timeframe.
Vol
Market Cap$116.5M
Cap SizeMicro Cap
Inst. Holders18 funds
Inst. Value$3.3M
Inst. Activity1 buys / 2 sells
SEC Reports3
Press Releases2
Recent Activity
Jun 16, 2026
earnings_calendar
RFL Q3 2026 Earnings Scheduled — 2026-06-16
Jun 11, 2026
SEC
Rafael Holdings reported Q3 fiscal 2026 financial results with minimal revenue ($179K) and a net loss of $4.2M ($0.08/sh
8-K — Impact 7/10
Jun 10, 2026
SEC
Rafael Holdings announced completion of the last patient's final 96-week visit in the pivotal Phase 3 TransportNPC study
8-K — Impact 5/10
Apr 22, 2026
SEC
Rafael Holdings announced an exclusive patent license from MIT covering the use of cyclodextrins in Alzheimer's patients
8-K — Impact 4/10
Mar 21, 2026
Insider
Polinsky David surrendered for taxes 2,318 shares
Chief Financial Officer @ $1.28 ($3.0K)
Mar 13, 2026
Insider
JONAS HOWARD S surrendered for taxes 9,826 shares
Exec Chairman, CEO & President @ $1.50 ($14.8K)
Jan 28, 2026
Insider
Sieger Markus was granted 29,528 shares
Director @ $1.27 ($37.5K)
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
89,138 shares ($111.4K)
Latest Reports
MIXED
8-K
7/10
Rafael Holdings reported Q3 fiscal 2026 financial results with minimal revenue ($179K) and a net loss of $4.2M ($0.08/sh
Jun 11, 2026
NEUTRAL
8-K
5/10
Rafael Holdings announced completion of the last patient's final 96-week visit in the pivotal Phase 3 TransportNPC study
Jun 10, 2026
BULLISH
Press
7/10
Rafael Holdings announced the last patient completed the final 96-week visit in its pivotal Phase 3 TransportNPC study f
Jun 10, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1.6M | — |
| BlackRock, Inc. | $457.0K | — |
| DIMENSIONAL FUND ADVISORS LP | $348.6K | — |
| VANGUARD FIDUCIARY TRUST CO | $256.2K | — |
| CITADEL ADVISORS LLC | $176.3K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 21, 2026 | Polinsky David | F | $3.0K |
| Mar 13, 2026 | JONAS HOWARD | F | $14.8K |
| Jan 28, 2026 | Sieger Markus | A | $37.5K |
18 institutional holders with $3.3M total value (2,630,426 shares) as of 2026-Q1. Top holders: VANGUARD, BlackRock,, DIMENSIONAL. Net selling activity: 2 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 1,259,911 | $1.6M | 48.1% | — |
| 2 | BlackRock, Inc. | 365,618 | $457.0K | 14.0% | — |
| 3 | DIMENSIONAL FUND ADVISORS LP | 278,910 | $348.6K | 10.6% | — |
| 4 | VANGUARD FIDUCIARY TRUST CO | 204,955 | $256.2K | 7.8% | — |
| 5 | CITADEL ADVISORS LLC | 141,000 | $176.3K | 5.4% | DOUBLED +344.0% |
| 6 | WELLS FARGO & COMPANY/MN | 103,351 | $129.2K | 3.9% | DOUBLED +340.2% |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 89,138 | $111.4K | 3.4% | ADD +59.1% |
| 8 | STATE STREET CORP | 62,170 | $77.7K | 2.4% | ADD +30.1% |
| 9 | Cerity Partners LLC | 44,732 | $55.9K | 1.7% | DOUBLED +128.7% |
| 10 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 23,278 | $29.1K | 0.9% | — |
| 11 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 18,599 | $22.7K | 0.7% | TRIM -29.8% |
| 12 | CITADEL ADVISORS LLC | 10,581 | $13.2K | 0.4% | DOUBLED +344.0% |
| 13 | MORGAN STANLEY | 9,808 | $12.3K | 0.4% | TRIM -37.3% |
| 14 | Vanguard Global Advisers, LLC | 7,763 | $9.7K | 0.3% | — |
| 15 | DEUTSCHE BANK AG\ | 325 | $406.00 | 0.0% | — |
| 16 | HRT FINANCIAL LP | 10,278 | $12.00 | 0.0% | TRIM -63.7% |
| 17 | CWM, LLC | 8 | $10.00 | 0.0% | — |
| 18 | CITIGROUP INC | 1 | $1.00 | 0.0% | NEAR_EXIT -99.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 56,027 | 89,138 | +59.1% | $111.4K | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | TRIM | 26,479 | 18,599 | -29.8% | $22.7K | 2026-Q1 |
| HRT FINANCIAL LP | TRIM | 28,282 | 10,278 | -63.7% | $12.00 | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 76,431 | 56,027 | -26.7% | $66.1K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 6,166 | 1,175 | -80.9% | $1.4K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 23,485 | 103,392 | +340.2% | $140.6K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 29,831 | 76,431 | +156.2% | $103.9K | 2025-Q3 |
| CITADEL ADVISORS LLC | DOUBLED | 16,349 | 72,584 | +344.0% | $98.7K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 16,001 | 10,038 | -37.3% | $13.7K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 1,537 | 6,166 | +301.2% | $8.4K | 2025-Q3 |
| BARCLAYS PLC | DOUBLED | 1 | 1,602 | +160100.0% | $2.2K | 2025-Q3 |
| HRT FINANCIAL LP | ADD | 16,365 | 23,776 | +45.3% | $32.00 | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 1,003,341 | 1,261,702 | +25.8% | $2.2M | 2025-Q2 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | ADD | 13,695 | 17,203 | +25.6% | $32.5K | 2025-Q2 |
| STATE STREET CORP | ADD | 46,352 | 60,284 | +30.1% | $112.7K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 72,591 | 28,331 | -61.0% | $53.0K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 1,866 | 23,482 | +1158.4% | $43.9K | 2025-Q1 |
| UBS Group AG | DOUBLED | 1,130 | 2,537 | +124.5% | $4.7K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 766 | 1,866 | +143.6% | $3.1K | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,138 | 837 | -26.4% | $1.4K | 2024-Q4 |
| CITIGROUP INC | NEAR_EXIT | 311 | 1 | -99.7% | $2.00 | 2024-Q4 |
| Cerity Partners LLC | DOUBLED | 20,301 | 46,429 | +128.7% | $90.1K | 2024-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 2,137 | 1,138 | -46.7% | $2.2K | 2024-Q3 |
3 unique insiders with 3 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 21, 2026 | Polinsky David | Chief Financial Officer | TAX W/H | 2,318 | $1.28 | $3.0K |
| Mar 13, 2026 | JONAS HOWARD S | Exec Chairman, CEO & President | TAX W/H | 9,826 | $1.50 | $14.8K |
| Jan 28, 2026 | Sieger Markus | Director | AWARD | 29,528 | $1.27 | $37.5K |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 5.3/10.
MIXED
8-K
7/10
Rafael Holdings reported Q3 fiscal 2026 financial results with minimal revenue ($179K) and a net los
Jun 11, 2026
NEUTRAL
8-K
5/10
Rafael Holdings announced completion of the last patient's final 96-week visit in the pivotal Phase
Jun 10, 2026
NEUTRAL
8-K
4/10
Rafael Holdings announced an exclusive patent license from MIT covering the use of cyclodextrins in
Apr 22, 2026
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 16, 2026
earnings_calendar
RFL Q3 2026 Earnings Scheduled — 2026-06-16
Jun 11, 2026
earnings
Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
<p>NEWARK, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter fisc
Jun 10, 2026
fda
Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
<p align="center"><em>Topline results are expected to be announced in second half of calendar 2026</em></p>
Apr 22, 2026
other
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”
License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatmen
Mar 18, 2026
earnings_calendar
RFL Q2 2026 Earnings Scheduled — 2026-03-18
Mar 16, 2026
earnings
Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results
<p align="justify">NEWARK, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the s
Mar 11, 2026
earnings_calendar
RFL Q2 2026 Earnings Scheduled — 2026-03-11